Immunis, Inc.
Industry
- Biotechnology
- Gene Therapy, Cell Therapy
- Pharmaceuticals
See more in Biomedtracker
Latest on Immunis, Inc.
Scrip
• By Mandy Jackson
Venture capital fundraising data show that $100m-plus mega-rounds continue to account for the vast majority of biopharmaceutical company VC financings, with overall investment in large rounds and indi
Scrip
• By Joseph Haas, Vibha Ravi, and Dexter Jie Yan
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck KGaA Pays $600m For Transfection